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More than ten years have elapsed since human papillomavirus (HPV) vaccination was implemented. We performed a 
systematic review and meta-analysis of the population-level impact of female-only HPV vaccination on HPV infections, 
anogenital wart diagnoses (AGW) and cervical intraepithelial neoplasia grade 2+ (CIN2+) to summarise the most recent 




We updated our prior review (01/01/2007–28/02/2014), by searching Medline and Embase (01/02/2014–11/10/2018) for 
studies that examined changes, between pre- and post-vaccination periods, in HPV infections, AGW, or CIN2+. We 
stratified all analyses by sex, age, and years since HPV vaccination introduction. We used random-effects models to 
estimate pooled relative risks and performed subgroup analysis to identify the main sources of heterogeneity.  
 
Findings 
We identified 65 eligible articles conducted in 14 high-income countries. After 5-8 years of vaccination, HPV-16/18, AGW, 
and CIN2+ decreased significantly by about 80%, 70%, and 50% among girls aged 15-19 years and by 65%, 55%, and 30% 
among women aged 20-24 years. Significant cross-protection and herd effects were also observed. HPV-31/33/45 decreased 
significantly by 50% among girls aged 15-19 years and AGW decreased significantly by 30-50% among boys/men aged 15-
24 years. After 5-8 years of vaccination, countries with multi-cohort vaccination and high coverage (≥50%) had greater 
reductions in AGW, 44 and 85 percentage points among girls and boys aged 15-19 years, respectively, than countries with 
single-cohort vaccination and/or low vaccination coverage.  
 
Interpretation 
Our meta-analysis, including data from >60 million individuals from 14 high-income countries, shows a substantial impact 
of female-only HPV vaccination programs on AGW among girls/women and boys/men, and HPV infections and CIN2+ 
among girls/women. In addition, programs with multi-cohort vaccination and high vaccination coverage lead to greater and 
faster direct impact and herd effects. 
 
Funding 




RESEARCH INTO CONTEXT  
 
Evidence before this study 
Since 2007, 99 countries and territories have introduced HPV vaccination programs.  In 2015, we conducted a systematic 
review and meta-analysis to examine the real-world population-level impact of HPV vaccination. The meta-analysis showed 
substantial decreases in HPV-16/18 infections and anogenital wart diagnoses among females targeted for vaccination, and 
evidence of herd effects among boys and older women, 4 years after the introduction of HPV vaccination. However, at the 
time of the meta-analysis, the number of years post-vaccination was insufficient to examine the impact of HPV vaccination 
on cervical intraepithelial neoplasia grade 2+ (CIN2+). Moreover, in 2016, the World Health Organization (WHO) Strategic 
Advisory Group of Experts on Immunization revised its position to recommend HPV vaccination of multiple age cohorts of 
girls, rather than vaccinating a single cohort.  
 
We updated our previous systematic review to 1) summarise the most recent evidence about the impact of HPV vaccination 
on HPV infections and anogenital wart diagnoses, 2) summarise new evidence about the impact of HPV vaccination on 
CIN2+, and 3) compare the impact between countries having implemented either a single or multiple age cohort vaccination 
strategy. To do so, we searched Medline and Embase (Feb 1, 2014 and October 11, 2018), without language restriction, with 
terms including  (“papillomavirus vaccine”, “papillomavirus vaccination”, “HPV vaccine”, or “HPV vaccination”) and 
(“program evaluation”, “population surveillance”, “sentinel surveillance”, “incidence”, or prevalence”), and 
(“papillomavirus infection”, “condylomata acuminata”, “anogenital warts”, “cervical intraepithelial neoplasia”, “cervical 
dysplasia”, “uterine cervical neoplasm”, or “HPV related diseases”). We identified 47 new eligible articles added to our first 
review for a total of 65 articles. We contacted all corresponding authors of eligible studies to request a re-analysis of their 
data using the same data stratification to allow comparison between studies and pooling. 
 
Added value of this study 
The current updated systematic review and meta-analysis, which includes data from 60 million individuals and up to 8 years 
of post-vaccination follow-up, shows compelling evidence of the substantial impact of HPV vaccination programs on HPV 
infections, anogenital wart diagnoses and CIN2+ among women, and herd effects among boys and older women. Our study 
also shows greater and faster direct impact and herd effects in countries with multiple age cohort vaccination and high 
vaccination coverage compared to countries with single age-cohort vaccination or low routine vaccination coverage.  
Our study is the first: 1) to present pooled estimates of the population-level impact of HPV vaccination on CIN2+, the most 
proximal outcome to cervical cancer recognized as a valid proxy for vaccine efficacy against cervical cancer, and 2) to show 
the real-world additional benefit of vaccinating multiple age cohorts of girls with high vaccination coverage.   
 
Implication of all available evidence 
Our results are the strongest yet that HPV vaccination is working to prevent cervical cancer in real-world settings, as both 
the cause (high-risk HPV infection) and proximal disease endpoints are significantly declining. In terms of global policy 
implications, these results reinforce the recently revised position of the WHO recommending HPV vaccination of multiple 
age cohorts of girls and are promising early signs that the WHO call for action on cervical cancer elimination may be 
possible if sufficient population-level vaccination coverage can be reached.  
 5 
INTRODUCTION 
More than ten years after the licensure of the first human papillomavirus (HPV) vaccines, 99 countries and territories have 
introduced HPV vaccination programs.
1, 2
 Observational data showing the population-level impact of HPV vaccination from 
the early adopting countries can be immensely useful for decision makers examining whether to introduce or modify HPV 
vaccination programs. This is because such data demonstrate the effectiveness of HPV vaccines in real-world settings and 
can assist in the identification of the program characteristics that lead to the greatest reductions in HPV-related infections 
and diseases.  
 
In 2015, we conducted a systematic review and meta-analysis of the population-level impact of HPV vaccination, including 
data from nine high-income countries up to four years after the introduction of HPV vaccination.
3
 Our meta-analysis 
showed substantial decreases in HPV-16/18 infections and anogenital wart diagnoses among girls and young women 
targeted for vaccination. Furthermore, in countries with high vaccination coverage (≥ 50%), there was evidence of vaccine 
cross-protection and herd effects, with statistically significant reductions in HPV-31/33/45 infection among girls targeted 
for vaccination and anogenital wart diagnoses among unvaccinated boys and older women, respectively. However, in this 
previous meta-analysis, the number of years post-vaccination was insufficient to examine the impact of HPV vaccination on 




In this paper, we update our systematic review and meta-analysis for three main reasons. Firstly, the number of countries 
and studies reporting observational data of the population-level impact of HPV vaccination has increased dramatically since 
our first review, which will improve both the power and generalizability of results. Secondly, the number of years post-
vaccination has increased, which allows analysis of changes in CIN2+ since the introduction of HPV vaccination. Thirdly, 
the World Health Organization’s (WHO) Strategic Advisory Group of Experts on Immunization revised its position in 2016 
to recommend HPV vaccination of multiple age cohorts of girls when introducing the vaccine in a country, rather than 
vaccinating a single age cohort.
5
 Prior to this recommendation, some high-income countries had implemented multiple age-
cohort vaccination, mainly through catch-up campaigns. A better understanding of the population-level impact of multiple 
age-cohort vaccination will help inform policy-makers’ decisions regarding whether to follow the recent WHO 
recommendation.  
 
Thus, the aims of this systematic review and meta-analysis are to: 1) update and summarise the most recent evidence about 
the population-level impact of girls-only HPV vaccination on HPV infections and anogenital wart diagnoses among girls, 
women, boys and men, 2) summarise new evidence about the population-level impact of girls-only HPV vaccination on 
CIN2+ occurrence among screened girls/women, and 3) compare the population-level impact of HPV vaccination on 




Search strategy and selection of articles 
In this updated systematic review, we used the same search strategy as our previous paper
3
 and report our methods in 
accordance with the PRISMA guidelines (Appendix Table S1).
6
 Briefly, studies were eligible if they compared the 
frequency (prevalence or incidence) of at least one HPV-related endpoint: 1) genital HPV infections, 2) anogenital wart 
diagnoses, or 3) histologically confirmed CIN2+, between the pre- and post-vaccination periods, among the general 
population and using the same population sources and recruitment methods pre- and post-vaccination. For CIN2+, the 
population was restricted to screened girls/women, to limit the impact of changes in screening 
recommendations/participation since the introduction of HPV vaccination. Finally, because our aim was to examine the 
population-level impact of HPV vaccination programs, we excluded studies if HPV vaccination was administered as part of 
a randomized trial, and/or if there were no data available for the pre-vaccination period.  
 
To update our first systematic review (Jan 1, 2007 to Feb 28, 2014), we searched Medline and Embase between Feb 1, 2014 
and October 11, 2018, with the same combination of Medical Subject heading (MeSH) terms, title, or abstract words 
(“papillomavirus vaccine”, “papillomavirus vaccination”, “HPV vaccine”, or “HPV vaccination”) and (“program 
evaluation”, “population surveillance”, “sentinel surveillance”, “incidence”, or prevalence”), and (“papillomavirus 
infection”, “condylomata acuminata”, “anogenital warts”, “cervical intraepithelial neoplasia”, “cervical dysplasia”, “uterine 
cervical neoplasm”, or “HPV related diseases”) (Appendix Table S2). The identification of eligible articles was performed 
independently by EB or NP and MD on title and abstract first, and then on the full-text. Disagreement between reviewers 
was solved by discussion between those authors.  Finally, we searched the reference lists of selected articles. If more than 
one publication from the same data sources and/or research team was available, we kept the publication presenting the most 
recent or exhaustive data. 
 
Data extraction and quality assessment 
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Our primary outcome was the relative risk (RR) comparing the frequency (prevalence or incidence) of HPV-related 
endpoints between the pre- and post-vaccination periods. For HPV infection, we focussed on three subgroups of HPV types: 
1) HPV-16/18, 2) HPV-31/33/45, 3) all high-risk types except HPV16/18. MD, EB, and NP extracted the study 
characteristics and outcomes using a standardised form. MD, EB, NP and MB assessed the methodological quality of all 
studies, independently from the authors of the original studies, using the criteria developed for our first systematic review 
(Appendix Tables S5-S7). Potential biases and confounding were assessed by examining the procedures to select or identify 
participants, endpoint definitions, algorithms used to identify cases, and potential confounders (specific to each HPV-related 
endpoint) considered in the analysis. Then, MD contacted all corresponding authors of eligible studies to request a re-
analysis of their data using the same data stratifications (e.g., age groups, HPV type grouping) to allow comparison between 
studies and pooling and all authors were able to provide these data. In collaboration with authors from the different 
countries, MD, EB, and NP also collected detailed information about the characteristics of each country/region HPV 
vaccination programs (routine program and catch-up campaigns), vaccination coverage, and cervical cancer screening 
recommendations/participation (Appendix Tables S3-S4). Finally, all authors of eligible studies validated that the 
information and data from their study, which were included in the manuscript, were accurate. 
 
Data analysis 
For all endpoints, we stratified all analyses by sex, age and years since the introduction of HPV vaccination. A priori, we 
chose to present the RRs stratified into two time categories to reflect the post-vaccination follow-up period used in our first 
meta-analysis (1-4 years), and the additional years available for the current update (5-8 years for HPV infections and 
anogenital warts / 5-9 years for CIN2+). In addition, we stratified analyses for anogenital warts by the type of vaccine (since 
only the quadrivalent vaccine includes HPV-6/11, which are associated with 85-95% of anogenital warts
7
). We used 
prevalence or incidence rate ratios as the measure of effect for all HPV-related endpoints (according to the data available 
from each study). For HPV infections, most studies directly presented crude and/or adjusted relative risk (RR) with 95% 
confidence intervals (CI). We preferably included RR adjusted for indicators of sexual activity and/or socio-economic status 
in the meta-analysis, but we used crude RR if adjusted estimates were not available. For anogenital warts and CIN2+, 
studies presented the annual frequency (prevalence or incidence) of the endpoint over time for the pre- and post-vaccination 
periods. Hence, for these endpoints, we estimated pre-vaccination frequency by aggregating the data for up to 3 years before 
vaccination and calculated crude RR by dividing each post-vaccination year by the pre-vaccination estimate (Appendix 
Table S8). We used random-effects models on a log scale to obtain pooled estimates of the effect of HPV vaccination for 
each HPV-related endpoint,
8, 9
 using Review Manager version 5.3.5. We used I² and χ² statistics to assess heterogeneity 
across studies, and the p value associated with the χ² statistic represents the statistical significance of heterogeneity.10 
 
The number of studies available for each HPV-related endpoint was too small to perform multivariate meta-regression.
10
 
Therefore, we performed subgroup analyses to identify the main sources of heterogeneity between studies. Firstly, we 
examined the impact of vaccination coverage and number of vaccinated cohorts, given that vaccination of a single or 
multiple cohorts is a key policy question. Because HPV endpoints were estimated from different types of studies, the 
available information about vaccination coverage and number of cohorts vaccinated varied across type of endpoints. For 
HPV infections, the vaccination status was directly available for all study participants (except for Dillner et al.
11
). Hence, we 
used the age-specific proportion of individuals vaccinated with at least one dose in each study and dichotomized the studies’ 
vaccination coverage into < 50% and ≥ 50%. For anogenital warts, most studies were based on population or insurance 
registries of a country/region. Hence, we used the overall proportion of people vaccinated in the country/region and 
dichotomized the studies’ country/region into: 1) Medium/high proportion of people vaccinated: country/region vaccinating 
multiple cohorts of girls with a vaccination coverage ≥ 50% for at least 2 doses among the routine cohort, and 2) Low 
proportion of people vaccinated: country/region vaccinating a single cohort of girls and/or having a coverage for at least 2 
doses < 50% among the routine cohort. For CIN2+, studies were based on screened girls/women from screening registries. 
However, because the vaccination coverage was not available for screened girls/women for all studies, we used the overall 
country/regional level data and used the same categories as for anogenital warts (see Appendix Table S3). Secondly, we 
examined the impact of the vaccine used (bivalent, quadrivalent) and the data source (population-based, health 
provider/insurance-based, clinic-based) for all endpoints. Thirdly, we examined relevant endpoint-specific sources of 
heterogeneity. Because studies on HPV infection reported either adjusted or crude RR, we examined the impact of RR 
adjustment (yes, no). Finally, because CIN2+ detection can be influenced by screening recommendations/participation, we 
examined the potential impact of using HPV testing (yes, no) during the study period and the potential impact of changes 
that occurred during the study period: introduction of HPV testing (yes, no), older age at screening start (yes, no), and 




Role of the funding source 
 7 
The funders had no role in the study design, data collection, analysis and interpretation, or writing of the report. MB had full 
access to all the data in the study and had final responsibility for the decision to submit for publication. 
  
RESULTS 
We identified 1702 potentially eligible new articles (published between Feb 1, 2014 and Oct 11, 2018), of which 47 eligible 
articles were added to our first review for an overall total of 65 articles included in this systematic review (23 articles for 
HPV infection,
11-33
 29 articles for anogenital warts,
34-62
 and 13 articles for CIN2+
63-75
) (Figure 1). These studies were 
conducted in fourteen high-income countries and cumulated data from more than 60 million individuals over 8 years (2007-
2015) (Table 1). The vaccination programs, vaccination coverage (Appendix Table S3), and cervical screening 
recommendations/participation (Appendix Table S4) varied substantially between countries. As of 2015 (year of the most 
recent available data), 12/14 countries included in the review were vaccinating females-only with 3 doses of the bivalent or 
quadrivalent vaccine (Appendix Table S3). The only exceptions were Australia and the USA. Australia switched to a 
gender-neutral program in 2013 (i.e., year 6 after the implementation of HPV vaccination) and the USA recommended 
gender-neutral vaccination in 2011 (2-dose vaccination coverage among males remained below 20% until 2013, year 7 after 
the implementation of HPV vaccination). The age of girls/women targeted for vaccination also varied between countries 
(Appendix Table S3). The age of routine vaccination varied slightly between countries, from 10 to 13 years old. Most 
countries with multi-cohort vaccination targeted girls up to 18 years of age through routine and catch-up programs. 
However, Australia, the USA, and Denmark targeted women up to 26 years of age (with decreasing coverage as age 




In the first four years following the introduction of HPV vaccination, HPV-16/18 prevalence decreased significantly among 
girls aged 13-19 years and women aged 20-24 years compared to the pre-vaccination period (Figure 2, Appendix Figure 
S1). After 5-8 years of vaccination, HPV-16/18 prevalence decreased significantly by 83% (RR 0·17 [95% CI 0·11–0·25]) 
and 66% (RR 0·34 [95% CI 0·23–0·49]) among girls aged 13-19 years and women aged 20-24 years, respectively, 
compared to the pre-vaccination period. No significant changes in HPV-16/18 prevalence were observed among women 
aged 25-29 years (mostly unvaccinated) during the first four years of vaccination whereas a significant decrease was 
observed during the 5-8 year follow-up period (RR 0·63 [95% CI 0·41-0·97].  
 
For HPV-31/33/45 (cross-protective types), there were substantial but non-significant decreases in prevalence during the 
first 4 years of vaccination among girls aged 13-19 years. However, after 5-8 years of vaccination, HPV-31/33/45 
prevalence decreased significantly by 54% (RR 0·46 [95% CI 0·33–0·66]) among girls aged 13-19 years and non-
significantly by 28% (RR 0·72 [95% CI 0·47–1·10]) among women aged 20-24 years. No significant changes in HPV-
31/33/45 prevalence were observed among women aged 25-29 years during the 0-4 and 5-8 year follow-up periods. Finally, 
although non-significant, slight increases in the prevalence of high-risk types not included in the vaccine were observed for 
all age groups.  
 
In subgroup analyses, studies where participants had a high vaccination coverage (≥ 50%) generally had greater decreases in 
HPV-16/18 and HPV-31/33/45 prevalence compared to studies with a low vaccination coverage (<50%), but the differences 
were not always statistically significant (Appendix Table S9). Studies using clinic-based data also showed greater decreases 
in HPV-16/18 prevalence compared to studies using population-based data. Studies with a high vaccination coverage and/or 
using clinic-based data showed greater increases in high-risk HPV types other than 16/18 among girls aged 13-19 years and 
during the first 4 years of vaccination. However, these differences were not maintained with a longer post-vaccination 
follow-up and were not consistent across the different age groups. 
 
Only two studies were available for genital HPV infections among males (Appendix Figure S1 D,E).
13, 31
 Non-significant 
decreases in HPV-16/18 (RR 0·35 [95% CI 0·09–1·40]) and HPV 31/33/45 (RR 0·31 [95% CI 0·06–1·58]) prevalence were 
observed among boys aged 16-19 years during the first 4 years of girls-only vaccination. The decreases were very similar 
after 5-8 years of vaccination in the study by Chow et al.
13
 No significant changes were observed among men aged 20-24 
years. 
 
Anogenital Wart Diagnoses     
In the first four years following the implementation of quadrivalent HPV vaccination, anogenital wart diagnoses decreased 
significantly among girls/women aged 15-19, 20-24 years, and 25-29 years. In addition, non-significant but substantial 
decreases were observed among unvaccinated boys aged 15-19 years (Figure 3, Appendix Figure S2). After 5-8 years of 
HPV vaccination, declines in anogenital wart diagnoses were significant for girls/women aged 15-29 years and for 
boys/young men (Figure 3). Anogenital wart diagnoses decreased significantly by 67% (RR 0·33 [95% CI 0·24–0·46]) and 
31% (RR 0·69 [95% CI 0·53–0·89]) among girls aged 15-19 years and women aged 25-29 years, respectively, and by 48% 
 8 
(RR 0·52 [95% CI 0·37–0·75]) and 32% (RR 0·68 [95% CI 0·47–0·98]) among boys aged 15-19 years and young men aged 
20-24 years, respectively. Three studies examined changes in anogenital wart diagnoses following the implementation of 
bivalent vaccination and results suggest a slight decrease among girls/women aged 15-19 and 20-24 years, and boys aged 
15-19 years (Appendix, Figure S2 A,B, E, F). 
 
In subgroups analyses, studies conducted in countries with multi-cohort vaccination and a population-level vaccination 
coverage ≥ 50% consistently showed greater decreases in anogenital wart diagnoses among females and males and among 
different age groups (Appendix, Table S10). Studies using clinic-based data also showed greater decreases of anogenital 
wart diagnoses compared to studies using population-based data.  
 
Figure 4 shows changes over time in anogenital wart diagnoses among females and males, taking into consideration the 
main sources of heterogeneity. This figure clearly illustrates the rapid and significant decline in anogenital wart diagnoses 
over time among girls/women and boys/men aged 15-19, 20-24 and 25-29 years, in countries vaccinating multiple cohorts 
of girls/women with high routine vaccination coverage. On the other hand, the decline was slower in countries vaccinating a 
single cohort of girls or having low routine vaccination coverage, with significant decreases observed among girls/women 
aged 15-19 and 20-24 years, only in the third years of vaccination. In addition, in these countries, increases in anogenital 
wart diagnoses were observed among the oldest cohorts of men (Figure 4B). A sensitivity analysis restricted to countries 
with high vaccination coverage (≥50%), showed that multi-cohort vaccination provided substantial additional reductions in 
anogenital wart diagnoses than single-cohort vaccination (Appendix Figure S4). 
 
CIN2+ 
In the first four years following the introduction of HPV vaccination, significant CIN2+ decreases were only observed 
among screened girls aged 15-19 years (Figure 5, Appendix Figure S3). After 5-9 years of HPV vaccination, CIN2+ 
decreased significantly by 51% (RR 0·49 [95% CI 0·42–0·58]) and 31% (RR 0·69 [95% CI 0·57–0·84]) among screened 
girls aged 15-19 years and women aged 20-24 years, respectively. However, during the same follow-up period, CIN2+ 
increased significantly by 19% RR 1·19 [95% CI 1·06–1·32]) and 23% (RR 1·23 [95% CI 1·13–1·34]) among screened and 
mostly unvaccinated women aged 25-29 and 30-39 years, respectively.  
 
In subgroup analyses, countries with multi-cohort vaccination and high routine vaccination coverage produced greater 
decreases in CIN2+ among girls/women aged 15-24 years old than the country with single-cohort vaccination and/or low 
routine vaccination coverage (Appendix, Table S11). The only study from a country using the bivalent vaccine also showed 
greater decreases in CIN2+ among women aged 20-24 years, compared to studies from countries using the quadrivalent 
vaccine (although the country using the bivalent vaccine also had very high vaccination coverage). Subgroup analyses also 
showed that increases in CIN2+ among women aged 25-29 years during post-vaccination years were significantly greater in 
the country with single-cohort vaccination and/or low routine vaccination coverage. None of the variables related to changes 
in screening recommendations/participation since the introduction of HPV vaccination were clearly associated with changes 
in CIN2+.  
 
Figure 6 shows changes in CIN2+ among screened girls/women, taking into consideration the main sources of heterogeneity 
(excluding the results from the only country with single-cohort vaccination). Significant declines in CIN2+ were observed 
among girls aged 15-19 years and women aged 20-24 years after one and three years of vaccination, respectively. On the 




This systematic review and meta-analysis, including data from 14 high-income countries, shows a significant and 
substantial impact of HPV vaccination on three HPV-related endpoints in the first 9 years after the start of HPV vaccination. 
Over this time period, HPV-16/18 infections, anogenital wart diagnoses and CIN2+ decreased significantly by about 80%, 
70%, and 50%, respectively, among girls aged <20 years, and by 65%, 55%, and 30% among women aged 20-24 years. 
There was also evidence of vaccine cross-protection and herd effects from girls-only vaccination programs. HPV-31/33/45 
decreased significantly by 50% among girls aged <20 years, and anogenital wart diagnoses decreased significantly by 30-
50% among boys/men aged 15-24 years and by 30% among women aged 25-29 years. Finally, our meta-analysis illustrates 
the greater and faster direct impact and herd effects of HPV vaccination in countries with both multi-cohort vaccination and 
high routine vaccination coverage compared to countries with single-cohort vaccination and/or low routine vaccination 
coverage. For example, after 5-8 years of HPV vaccination, anogenital wart diagnoses declined by 88% and 86% among 
girls and boys aged <20 years, respectively, in countries with multi-cohort vaccination and high routine vaccination 
coverage compared to 44% and 1% in countries with single-cohort vaccination and/or low routine vaccination coverage.   
 
 9 
Our study is the first to show the real-world additional benefit of multi-cohort HPV vaccination and high routine 
vaccination coverage. After 5-8 years of vaccination, reductions in anogenital wart diagnoses and CIN2+ among girls aged 
15-19 years were 44 and >100 percentage points greater, respectively, compared to countries with single-cohort vaccination 
and/or low routine vaccination coverage. Fast and substantial herd effects were also observed in countries with multi-cohort 
vaccination and high routine vaccination coverage. After 5-8 years of girls-only vaccination, reductions in anogenital wart 
diagnoses were 85 percentage points greater among boys aged 15-19 years old compared to single-cohort vaccination and/or 
low routine vaccination coverage. These results were similar when restricting the analysis to countries with high routine 
vaccination coverage. Our results are also in line with a recent mathematical modeling study, which estimated that five 
years after the introduction of HPV vaccination in Australia, half of the observed declines in anogenital wart diagnoses were 
attributable to multi-cohort vaccination (catch-up of 14-26-year-old females) (Appendix Table S3).
76
 In terms of policy 
implications, these results reinforce the recently revised position of the WHO, recommending HPV vaccination of multiple 
age cohorts of girls (9-14 years old) when introducing the vaccine in a country, rather than vaccination of a single cohort,
5
 
to obtain faster and greater population-level impact. However, the optimal number of age cohorts to vaccinate remains an 
open question and may be country specific. Increasing the number of cohorts will increase the population-level impact, but 
with diminishing returns on investment for each additional older cohort included. Number needed to vaccinate (NNV) and 
cost-effectiveness analyses in high income countries suggest that vaccinating multiple cohorts up to 18 years old is highly 
efficient and cost-effective.
76, 77
 However, efficiency (effectiveness per vaccine dose) decreases after 18 years of age, as a 
high proportion of individuals will already have been infected by HPV vaccine types at the time of vaccination, and 3 doses 
are required (vs the recent recommendations of 2 doses for persons vaccinated before age 15 years 
78, 79
). Hence, 
decisions/recommendations about the number of age cohorts to be vaccinated is a trade-off between goals of maximising 
population-level impact (e.g., to reach HPV or cervical cancer elimination goals within a specific time frame) or optimising 
vaccination efficiency and return on investment (e.g., NNV and incremental cost-effectiveness ratios).  In addition, several 
key factors such as competing priorities, and vaccine affordability and availability can also influence decisions about multi-
cohort vaccination. Finally, our results also have implications for the interpretation of surveillance studies. The number of 
cohorts vaccinated should be considered in addition to the vaccination coverage when comparing surveillance data between 
countries, as the main driver of HPV vaccination impact is the total percent of the population vaccinated.  
 
Importantly, we also present the first pooled estimates of the population-level impact of HPV vaccination on CIN2+, which 
is the most proximal outcome to cervical cancer and is recognised as a valid proxy for vaccine efficacy against cervical 
cancer by regulatory agencies worldwide.
80-83
 The results are the strongest yet that HPV vaccination is working to prevent 
cervical cancer in real-world settings, as both the cause (high-risk HPV infection) and proximal disease endpoint are 
significantly declining. These results can also inform potential changes to cervical screening programs. Substantial declines 
in high-risk HPV types and CIN2+ may allow for older age of start of screening and longer screening intervals. However, 
when examining changes in screening in the era of vaccination, careful attention will have to be focussed on unvaccinated 
cohorts of women. The decreasing HPV prevalence observed in several settings also support arguments in favour of 
switching from cytology alone to primary HPV testing followed by cytology triage to benefit from the higher sensitivity of 
HPV testing to detect pre-cancer lesions and higher specificity of cytology, without substantially increasing false positive 
results.
84
.  However, CIN2+ surveillance data among screened girls/women should be interpreted with caution. First, the 
greatest and fastest reductions in CIN2+ are among an age group (15-19 years old) not always recommended for screening, 
and in which the proportion of those screened has been declining both before and since the introduction of HPV vaccination 
due to efforts in the countries to improve adherence to guidelines (Appendix Table S4). Therefore, although we restricted 
our analysis to screened girls/women, changes towards a lower risk profile among those that are still screened in this age 
group could partly contribute to decreases in CIN2+. However, to our knowledge, there is currently no data supporting 
changes in the risk profiles of screened women in the younger age groups since the introduction of HPV vaccination.  
Second, several studies have shown that participation in cervical screening and vaccination uptake are associated with the 
same socio-demographic factors (e.g., ethnicity, socioeconomic level, education),
85-90
 and therefore vaccination coverage 
among screened girls/women may be different 
91
, and potentially higher, than country/regional level vaccination coverage in 
some settings. Thirdly, major recent changes in screening recommendations, clinical management recommendations, and/or 
participation have been documented in several countries in the years surrounding the introduction of HPV vaccination. For 
example, the use of HPV testing (mainly as triage of low-grade lesions, which led to increased colposcopy referrals) and/or 
longer routine screening intervals, which are likely to increase the CIN2+ detection rate,
65
 have been reported in the USA, 
Denmark, and Norway (Appendix, Table S4). As done in the Scottish study,
75
 future surveillance studies should include, if 
possible, the vaccination coverage of screened girls/women to more accurately quantify the impact of HPV vaccination on 
CIN2+. 
 
By examining three main HPV-related endpoints concurrently, we can better understand trends in post-vaccination 
surveillance data, and draw stronger conclusions about the population-level effectiveness and herd effects of HPV 
vaccination. Of particular interest are the results suggesting increases in HPV-related endpoints among population 
subgroups not targeted by vaccination: 1) high-risk non-vaccine HPV types, 2) anogenital wart diagnoses among men aged 
 10 
25-39 years (particularly in countries with single-cohort vaccination and/or low vaccination coverage of girls), and 3) 
CIN2+ among screened women aged 25-39 years. Data from several countries suggest that increases in anogenital warts 
diagnoses 
34, 38, 43, 47, 50, 54
 and CIN2+ 
63, 92
 began before the introduction of HPV vaccination. Together, these results suggest 
that the population-level impact of HPV vaccination could currently be measured within an underlying context of increasing 
HPV-related endpoints in some countries. Although the reasons for these trends are likely multi-factorial and endpoint-
specific, several hypotheses can be made. First, increases in the three HPV-related endpoints could reflect increases in 
sexual activity. Several data sources indicate that, over the past 10 to 20 years, the number of sexual partners has increased 
and/or the age at sexual initiation has decreased in several high-income countries.
24, 93-101
 Second, endpoint-specific 
hypotheses could also explain observed increases. Increases in high-risk non vaccine HPV types could partly be explained 
by HPV-16/18 unmasking (i.e., apparent increased detection of non-vaccine HPV types in a post-vaccination population 
with fewer HPV-16/18 infections, which could have masked detection of other HPV types prior to vaccination) 
102
 or less 
likely by type-replacement (i.e., increased prevalence of non-vaccine HPV types occupying the ecological niche created by 
preventing HPV-16/18 infections).
103
 Increases in anogenital wart diagnoses could be partly explained by increased 
knowledge, awareness, and health seeking behaviour of the general population about anogenital warts and/or better 
diagnosis/reporting by health professionals. Finally, as previously discussed, increases in CIN2+ could be attributable to 
changes in screening recommendations, tests, and/or participation documented in several countries. More research is needed 
to better understand the factors influencing the increases in trends in non HPV vaccine types and HPV-related diseases in 
older females and males. If they are due to changes in sexual behaviour or increased health seeking behaviour/diagnoses, 
population-level effectiveness may be underestimated when comparing the annual frequency of HPV-endpoints between 
pre- and post-vaccination periods.  
 
In addition to the epidemiological and public health insights discussed above, our study has important additional strengths. 
All corresponding authors were contacted in order to have standardized age groups and HPV-endpoints permitting pooling 
of results. Furthermore, the large pooled sample size of person-time at risk and 8-year follow-up since the introduction of 
HPV vaccination gave sufficient statistical power to demonstrate declines in all three HPV-related endpoints among 
girls/women targeted for vaccination in both high and low coverage settings, and cross-protection and herd effects in 
countries with high vaccination coverage and multi-cohort vaccination. Our results should however be interpreted 
considering the following three limitations. First, because this meta-analysis is based on ecological studies, causality 
between HPV vaccination and the observed changes in HPV-related endpoints cannot be concluded definitively. However, 
the: 1) larger and faster decreases in HPV-related endpoints among cohorts targeted for vaccination and in countries with 
multi-cohort vaccination and high routine vaccination coverage, 2) larger decreases in HPV-related endpoints with longer 
follow-up since the introduction of HPV vaccination (as the number of cohorts vaccinated increases), and 3) consistency 
between the results from the different studies and between the three HPV-related endpoints, strongly suggest that the 
decreases can be largely attributed to HPV vaccination. Second, the number of post-vaccination studies is not yet sufficient 
to perform multivariate meta-regression in order to simultaneously consider the influence of different program 
characteristics or study designs. In addition, the number of studies within categories is sometimes limited. For example, 
greater decreases in CIN2+ were observed in the only study using the bivalent vaccine (from Scotland) compared to the 
studies using the quadrivalent vaccine. However, it was not possible to tease out the effect of the vaccine type given that 
Scotland has very high HPV vaccination coverage, had catch-up vaccination, and had no major change in screening 
recommendation/behaviour since the introduction of HPV vaccination. Third, our results should be extrapolated to low- and 
middle-income countries with caution, as all studies identified in the systemic review are from high-income countries. The 
population-level impact of HPV vaccination, including the impact of multi-cohort vaccination strategies, may be different in 
countries that have substantially different sexual behaviour (e.g., age at start of sexual activity, age-difference between 
partners, concurrency in partnerships, percent of men that are clients of female sex workers), HPV epidemiology, and/or 
prevalence of HPV infection/disease cofactors (e.g., HIV).  
 
In conclusion, the results of this meta-analysis, including data from >60 million individuals from 14 high-income countries, 
show compelling evidence of the substantial impact of three-dose girls-only HPV vaccination programs with the 
quadrivalent or bivalent vaccines on infections by HPV-16/18 and 31/33/45 as a group, anogenital wart diagnoses and 
CIN2+ among women, and herd effects among boys and older women. In addition, programs with multi-cohort vaccination 
and high vaccination coverage lead to a greater and faster direct impact and herd effects. These results should be considered 
within the rapidly changing landscape of HPV vaccination, with several countries recently switching to 2-dose schedules, 
gender-neutral vaccination, and/or the nonavalent vaccine, and research examining 1-dose HPV vaccination, 2-doses in 
older populations, and cervical cancer elimination strategies. Although challenging, it will be crucial to continue monitoring 
the population-level impact of HPV vaccination to examine the full impact of these changes in vaccination strategies and to 
quantify the impact of vaccination in low- and middle-income countries.  
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Table 1. Characteristics of the studies included in the systematic review and meta-analysis 
Author 
(Country) 
Vaccine  Data source* Study population Population used 
in meta-analysis 
Data collection dates† Sample size used in 
meta-analysis ‡ 






HPV infection          
Chow 2015a 
Chow 2017 
(Australia) 12, 13 
Quadrivalent Clinic-based: STI 
clinics 
Females and males 15-25 
yrs attending the 
Melbourne Sexual Health 













HPV+ PapType HR HPV 
genotyping kit (Genera 
Biosystem) Females: 
cervical & vaginal swabs 











Primary care clinics 
Females 14-17 yrs 
attending 1 of 3 urban 








HPV+ Roche Linear Array 
(Roche, 37 types) 
OR of HPV 
prevalence 
(crude) 
RR of HPV 
prevalence 
(crude) 





Females 18-50 attending 
routine cervical cancer  
Females  










HPV+ Luminex system 









Quadrivalent Clinic-based: Kaiser 
Permanente 
NorthWest 
Females 20-29 yrs 









HPV+ Roche Linear Array 
& HPV-52 quantitative 
PCR 
RR of HPV 
prevalence 
(crude) 





Quadrivalent Clinic-based: Youth 
clinic in Stockholm 
Females and males (oral 
infections for males) 15-
23 yrs attending a 
Stockholm youth clinic 
Females   
15-23 yrsΩ 
Prevaccine: 2008-2011 




N postvaccine: 332 
HPV+ Luminex-based 













screening Call & 
Recall System  
Females 20-21 yrs 
participating in cervical 










HPV+ Multimetrix HPV 











Hospital and health 
department 
Females 13-26 yrs 
attending 1 hospital-based 
teen clinic and 2 health 
department sites in 
Cincinnati 
Females  
13-26 yrs,  








HPV+ Roche Linear Array 










Vaccine  Data source* Study population Population used 
in meta-analysis 
Data collection dates† Sample size used in 
meta-analysis ‡ 










Quadrivalent Clinic-based: Family 
planning clinics 
Females 18-35 yrs 
attending family planning 
clinics in Victoria and 
New South Wales 
Females 





2005-2007: HPV+ Roche 
Linear Array (13 types), 
2015: Cobas HPV test 
(Roche Diagnosis) and 
Roche Linear Array 
genotyping test (37 types) 
RR of HPV 
prevalence 
(adjusted) 











sample of USA females 









HPV+ Roche Linear Array 
(Roche, 37 types) 
RR of HPV 
prevalence 
(adjusted) 









health clinics, GP 
Females 16-24 yrs 
undergoing chlamydia 
screening in community 
sexual health / GP /Youth 










2008: Hybrid Capture 2 and 
Roche Linear Array 
≥2010: HPV+ In-house 
multiplex PCR and 
Luminex-based genotyping 
(18 types)‖  
OR of HPV 
prevalence 
(adjusted) 




2018 (Spain) 29 
Bivalent Clinic-based: 




Females 18-26 yrs 
attending  health areas of 








HPV+ Cobas 4800 HPV 
test with Linear Array HPV 
genotyping (Roche 
Diagnostic) (12 types) 













Females all ages 








HPV + In-house multiplex 
PCR with genotyping by 
MALDI-TOF mass 













sample of males and 
females aged 16-44 yrs 
Natsal-2, 16-74 yrs 













based genotyping assay (18 
types)‖  in urine samples 
OR of HPV 
prevalence 
(age-adjusted) 






Vaccine  Data source* Study population Population used 
in meta-analysis 
Data collection dates† Sample size used in 
meta-analysis ‡ 








Quadrivalent Clinic-based: Family 
planning clinics 
Females 18-24 yrs 
attending 1 of 6 family 
planning clinics in 









HPV+ Roche Linear Array 
(13 types),  
RR of HPV 
prevalence 
(adjusted) 
RR of HPV 
prevalence 
(adjusted) 
Anogenital warts     
Ali 2013/  
Chow 2015b, Ali 
2017, Callander 2016 
(Australia) 
34-37 
Quadrivalent Clinic-based: STI 
clinics  
New clients of 40 sexual 
health centers across 










P-yr prevaccine: 51,010 
P-yr postvaccine: 
134,614 
Clinical diagnosis Annual 
proportion of 
new clients with 
AGW 










Entire population of 
























Quadrivalent Health provider 
/insurance-based: 
Clinical encounters 
claims data of a 
health program 
Clients of the California 
Family Planning access 
care & treatment (PACT) 
program aged ≥ 10 yrs 
(87% females) 
Females and 











ICD-9 codes 078.10, 078.11 














Hospital records of 
all Veneto residents 
(public & private) 












ICD-9 code 078.11 and 1 
ICD-9 surgical code (70-71, 
58, 64, 58.3, 49) 
Annual rate of 
hospitalization 
for AGW in the 
population 





Quadrivalent Health provider 
/insurance-based: 
Medical claims, 
National Union of 
Independent Sick 
Funds (MLOZ) 
Enrollees in MLOZ, one 
of the 3 biggest sick fund 
in Belgium (18% of the 












First prescription of 
Imiquimod with a level of 
reimbursement specific for 
AGW onset 
RR of AGW 
incidence 
(crude) 






Vaccine  Data source* Study population Population used 
in meta-analysis 
Data collection dates† Sample size used in 
meta-analysis ‡ 

















approximately 100 health 
private insurance plans 




15-39 yrs,  
Insured 
employees, early 









1) ICD-9 codes 078.11 OR 
2) ICD-9 code 078.1, 
078.10, or 078.19 and 
therapeutic procedure  
diagnosis of benign AG 
neoplasm OR 3) ≥1 
prescription for AGW 
treatment and therapeutic 
procedure r diagnosis of 














(covers all Ontario 
residents) 
All Ontario residents 
aged ≥ 15 yrs with a valid 











First physician office visit 
(12-month wash-out period) 
with one of 10 possible 
combination codes: 099 + 
Z117, 079 + Z117, 629 + 
Z117, Z549, Z758, 
Females: Z733, Z736, or 
Z769; males Z767, Z701 
Annual 




RR of AGW 
incidence 
(crude) 







Patients of 1,000 
randomly selected GP 








P-yr prevaccine:  
77,258 
P-yr postvaccine: 
190,268   













(England) 47, 48 
Bivalent 
Quadrivalent 
for some girls 
15-16 yrs in 
2014-2015 α 
Population-based: 





Entire population of 











Clinical diagnosis  Annual 










Vaccine  Data source* Study population Population used 
in meta-analysis 
Data collection dates† Sample size used in 
meta-analysis ‡ 











Medical claims and 
hospital discharge 
database of all 
Manitoba residents 












Treatments (1 of 14 tariff 
codes) OR (hospitalization 
for AGW + ICD-9 code 
078.11) OR (078.1, 078.10, 
078.19 and related 
procedure) OR ICD-10 
A630 OR (B07 and related 
procedure) 
Annual 















Entire population of 











ICD-10 code A63.0 OR  
prescription of Imiquimod 
or Podophyllotoxin  
Annual 













All Australian women 
aged 18-39 yrs 
Females  
18-39 yrs 





P-yr postvaccine: 2,394 
Self-reported AGW 

















Enrollees in 1 large health 
insurance company across 











ICD-10 code A63.0 Annual 








(New Zealand)56, 57 
Quadrivalent Clinic-based: STI 
clinic 
New clients of 4 sexual 
health service in 







P-yr prevaccine:  9,559 
P-yr postvaccine: 
26,258 













Australian Bureau of 
Statistics 
Entire population of 












ICD-10 code A63.0 as main 
or contributory diagnosis 
Annual rate of 
hospitalization 
with AGW 
diagnosis in the 
population  






Vaccine  Data source* Study population Population used 
in meta-analysis 
Data collection dates† Sample size used in 
meta-analysis ‡ 






Sonnenberg 2017 60 Bivalent Population-based: 
Natsal participants 
Nationally representative 
sample of males and 
females aged 16-44 yrs 
Natsal-2, 16-74 yrs 













ever having a 
diagnosis of 
AGW  
RR of AGW 
proportion 
(crude) 
Steben 2018 61 Quadrivalent Health provider 
/insurance-based : 
Quebec physician 
claim and public 
drug insurance 
databases 
Individuals covered by 
the Quebec public drug 
insurance 
Females and 








ICD-9 code 078.1OR 
medical procedure specific 
to condyloma (05314, 
06169) OR dispensation of 
podofilox, imiquimod, or 
fluorouracil 
Annual 










PASSYON study in 
STI clinics 
Patients of STI clinics 





2009, 2011, 2013 
Prevaccine: 2009 
Postvaccine: 2011, 2013 








RR of AGW 
proportion 
(adjusted) 
Cervical intraepithelial neoplasia grade 2+   
Baldur-Felskov 
2014/2015  





Females aged ≥ 12 yrs 
living in Denmark and 
screened for cervical 
cancer 
















RR of CIN2+ 
incidence 
(crude) 
Benard 2017 (USA)65 Quadrivalent Population-based: 
New Mexico HPV 
pap registry 
Females aged 15-29 yrs 
living in New Mexico and 
screened for cervical 
cancer 

























Females aged <69 yrs 
living in Australia and 
























Vaccine  Data source* Study population Population used 
in meta-analysis 
Data collection dates† Sample size used in 
meta-analysis ‡ 















Females aged 15-39 yrs, 
enrolled in 100-170 
employers and health 
private insurance plans 
across USA and screened 
for cervical cancer 

































Females aged 18-39 yrs 
with a high-grade lesion 
in HPV-IMPACT (a 
laboratory-based 
surveillance system 
including areas from 
California, Connecticut, 



























(all 34 pathology 
laboratories). 
Number of screened 
women estimated 
from BRFSS 
Females aged 21-39 yrs 
living in Connecticut with 
a high-grade lesion in the 

















RR of CIN2+ 
incidence 
(crude) 
Nygård 2017 (via 
Liaw 2014) 





All females living in 

























BC Cervical cancer 
screening program 
registry 
Females aged 15-22 yrs 
living in British-
Columbia (Canada) and 
screened for cervical 
cancer 
Screened females 





















Vaccine  Data source* Study population Population used 
in meta-analysis 
Data collection dates† Sample size used in 
meta-analysis ‡ 












Females aged 20-21 yrs 
living in Scotland and 























AGW: Anogenital warts; AIHW: Australian Institute of Health and Welfare; BRFSS: Behavioral Risk Factor Surveillance 
System; NHANES: National Health and Nutrition Examination Survey; NATSAL: National Survey of Sexual Attitudes and 
Lifestyles; OR: Odds ratio; RR: Relative risk (Post-vaccination prevalence or incidence / Pre-vaccination prevalence or 
incidence); STI: Sexually transmitted infection: GP: General practitioner 
* Data sources are considered as: 1) Population-based when the study population includes the total population of a given 
country/region or a registry, 2) Health provider/insurance-based when the study population is constituted of a subgroup 
of the total population enrolled in a specific insurance plan, 3) Clinic-based when the study population is constituted of 
individuals who received health services (e.g., medical consultation). 
†
 For studies on HPV infection, the pre- and post-vaccination periods were already determined in most original 
publications (except for Kavanagh et al.). For studies on AGW and cervical lesions studies, the pre- and post-vaccination 
periods were determined for the purposes of this systematic review as described in the Appendix- Table S8.    
‡
 The sample size is restricted to the age groups used in the review. For studies on HPV infection, the pre and post-
vaccination sample sizes were already determined in original studies. For studies on AGW and cervical lesions, the pre-
vaccination sample size corresponds to the cumulative number of person-years up to three years pre-vaccination. The 
post-vaccination sample size corresponds to the cumulative number of person-years from 1 to 8 years after the 
introduction of vaccination, depending on data available in each study. 
ß 
For HPV infection, the investigators recalculated the RR (adjusted or crude) of prevalence using the original data from 
their specific studies. For AGW and precancerous lesions, we estimated pre-vaccination frequency by aggregating the 
data for up to three years prior to vaccination, and calculated RR by dividing each post-vaccination year by the pre-
vaccination estimate. 
** The study by Dillner et al. included data from Denmark, Sweden and Norway among women aged ≥ 18 years in 2012-
2013. However , since the vaccination program of 12 year-old girls began in 2009 in Norway, women included in the 
study (≥ 18 years old) were too old to be covered by the vaccination program (vaccination coverage < 2%). For this 
reason, we did not include data from Norway in the meta-analysis.    
Ω 
Since only oral infections were available for males, we did not include data for males from this study in our meta-
analysis. 
γ  
The pre-vaccine sample excludes 65 women who were vaccinated (10.6% of the sample). The prevalence of all HPV 
types, HPV 16/18, and other common HPV types did not statistically differ between the vaccinated and unvaccinated 
women of the pre-vaccination sample (unpublished data). 
Ŧ 
The study by Machalek includes a subset of women included in the studies by Tabrizi and a group of women aged 25-35 
years (not previously included in Tabrizi). To avoid double counting the same women, we only kept the results from the 
older group of women not previously included in Tabrizi. 
‖ 
 13 HR-HPV types were presented in the original publications whereas the 18 HR-HPV types available were used for the 
purposes of this meta-analysis 
Ψ 
Published data were available until 2012, but the author provided data up to 2015. 
α  
In 2014: 14% and 72% of 15 yr old girls received the quadrivalent and bivalent vaccine, respectively. In 2015, 57% and 
29% of 15 yr old girls received the quadrivalent and bivalent vaccine, respectively; 14% and 57% of 16 yr old girls 
received the quadrivalent and bivalent vaccine, respectively. 
¥
 Permission could not be obtained from the data custodian to release data in the age strata requested for this meta-
analysis, therefore results for age groups 15-19, 20-24, 25-29 and 30-39 years in this meta-analysis used published data 





Data from Brotherton et al. 2011 
66
 are restricted to the Victorian registry data. Supplementary data from the Australian 
Institute of Health and Welfare 2016 report were provided by Dr. Brotherton. Since the report covers all regions of 
Australia, it was used as our main data source for the review.   
£ 
The number of screened women is not directly available in these studies. Different data sources (individual or aggregate-
level) have been used to estimate the denominator (i.e., the number of screened women of the different catchment areas). 
€ 
One county from Connecticut (New Haven) is included in the HPV-IMPACT surveillance system. To avoid double 
counting women from this county in estimates from HPV-IMPACT (Gargano 2018) and Connecticut (Niccolai 2017), 
we decided with the authors, to excluded New Haven from the Connecticut data to keep them in HPV-IMPACT.  
Φ 
 CIN2+ data from Norway were identified in the article by Liaw et al 
73
 and were provided by Mari Nygård (personal 
communication) 
¶
 Data directly available in the article to estimate RR of CIN2+ incidence among screened females available only for 
females ages 15-17 years old.
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* 2 articles on anogenital warts from our previous review were not included in this update: 1) Sando et al:
104
 in our previous 
review, we identified two studies from Denmark analysing the entire Danish population for the same time period,
38, 104
 We 
included the Baandrup et al. study in our main analysis and verified that results were unchanged when using the Sando et 
al. study. Given that Baandrup et al. updated their data in a new publication, we kept this study with a longer follow-up for 
the current meta-analysis; 2) Nsouli-Maktabi:
105
 we excluded this study conducted among USA armed force members 
since we revised our eligibility criteria to exclude studies not conducted in the general population. 
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Figure 2. Changes in the prevalence of HPV infections between the pre-vaccination and post-vaccination periods (1-




Figure 3. Changes in anogenital wart diagnoses between the pre-vaccination and post-vaccination periods (1-4, 5-8 




Figure 4. Changes in anogenital wart diagnoses during the 8 years after the introduction of girls-only HPV 
vaccination in countries using the quadrivalent vaccine, stratified by number of cohorts vaccinated and routine 
vaccination coverage 
 













B) Boys and men  
   Single-cohort and high-coverage: Canada (Kliewer 2012/Thompson 2016, Guerra 2016), Italy (Cocchio 2017); Multi-
cohort and low coverage: Germany (Mikolajcyk 2013/Thöne 2017), Belgium (Dominiak-Fleden 2015), Sweden (Leval 
2012/Herweijer 2018), USA(Bauer 2012, Flagg 2013/2018) 
 Australia (Ali 2013/Callander 2016, Smith 2015, Harrison 2014, Liu 2014); Denmark (Baandrup 2013/Bollerup 2016); 
New Zealand (Oliphant 2011/2017), Canada (Steben 2018) 
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Figure 5. Changes in CIN2+ among screened girls/women between the pre-vaccination and post-vaccination periods 






Figure 6. Changes in CIN2+ among screened girls/women during the first 7 years after the introduction of girls-only 






















Australia (Brotherton 2011/AIHW2018), Canada (Ogilvie 2015), Denmark (Baldur-Felskov 2014), Scotland (Pollock 
2014), USA* (Flagg 2016, Niccolai 2017, Gargano 2018, Benard 2017) 
*  For CIN2+ analysis, USA was categorized as a country with multi-cohort vaccination and high routine vaccination 
coverage because several USA data indicate an association between screening participation and HPV vaccination.
86, 88, 89, 
91
 The vaccination coverage among screened girls/women is thus likely to be higher than the overall vaccination 
coverage in the population. We performed a sensitivity analysis excluding the USA from countries with multi-cohort 
and high vaccination coverage and results were unchanged. 
 
 
 
 
 
 
 
 
 
